Exciva GmbH, a Heidelberg, Germany-based clinical biotech company developing a novel therapeutic compound for treating agitation/aggression in Alzheimer’s disease, closed a €9m ($10M) Series A financing.
The round was led by Andera Partners with participation from LBBW Venture Capital and Cure8.
Click here to read the press release